Limnopharma signs an agreement with Inoviem Scientific and Hybrigenics (now Aton) to investigate the mode of action of lim21.
The agreement covers a 2 step process to establish how lim21 exerts its therapeutic effect. First, the target protein(s) interacting with lim21 will be identified using Inoviem’s NPOT proprietary technology. Then, this result will be validated by studying the interaction in detail in further in vitro experiments.
Inoviem Scientific and Aton are both France based biotech companies active in the drug discovery and drug development field.